Background and aims: To assess the reliability and validity of IMPACT-III (HR), a disease-specific, health-related quality of life instrument in Croatian children with inflammatory bowel disease. Methods: In a multicenter study, 104 children participated in a validation study of IMPACT-III (HR) cross-culturally adapted for Croatia. Factor analysis was used to determine optimal domain structure for this cohort, analysis of Cronbach's alpha coefficients to test internal reliability, ANOVA to assess discriminant validity, and correlation with Pediatric Quality of Life Inventory, Version 4.0 (PedsQL™) using Pearson correlation coefficients to assess concurrent validity. Results: Cronbach's alpha for the IMPACT-III (HR) total score was 0.92. The most robust factor solution was a 5-domain structure: Symptoms, Concerns, Socializing, Body Image, and Worry about Stool, all of which demonstrated good internal reliability (α = 0.60-0.89), but two items were dropped to achieve this. Discriminant validity was demonstrated by significant differences (P b 0.001) in mean IMPACT-III (HR) scores between quiescent and mild or moderate-severe disease activity groups for total (148 vs. 139 or 125) and following factor scores: Symptoms (84 vs. 71 or 61), Socializing (91 vs. 83 or 76), and Worry about Stool (significant only between quiescent and moderate-severe groups, 90 vs. 62, respectively). Concurrent validity of IMPACT-III (HR) with PedsQL™ showed significant correlation, which was strongest when similar domains were compared. A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
Health-related quality of life (HRQOL) has emerged as an important means of assessing the impact of the disease burden on health as well as determining the efficacy of medical care. 1 HRQOL measures patients' perception of their health status and how their disease affects physical, social, and emotional functioning. 2 Therefore, HRQOL complements information from disease activity indices and can evaluate how disease and treatment affect patients' lives. 3 When there is a chronic disorder, such as inflammatory bowel disease (IBD), evaluation of the quality of life is particularly important since the course of lifelong illness influences many areas of patient's functioning beyond physical health. 4 Unique to children and adolescents affected with IBD is the profound impact on growth, development and future functioning. 1, 4 HRQOL has been extensively investigated in adult IBD patients, but less research especially considering diseasespecific questionnaires has been conducted in pediatric IBD. 5 The first disease-specific HRQOL instrument for children with IBD was the IMPACT Questionnaire (or IMPACT-I) which was developed and validated in Canada more than a decade ago. 2, 6 Since then, several modifications were made: simplifying the wording of responses, some questions were rephrased and several additional questions were added resulting in the 35-item IMPACT-II Questionnaire, 7 Likert scale replaced original visual analogue scale, which finally resulted in IMPACT-III. 1 Currently, IMPACT-III is the questionnaire used for crosscultural adaptation 1 and it was applied along with its predecessors as an outcome measure in several research studies including three reliability and validation analyses. 2, 8, 9 The objective of this study was to ensure that, after the cross-cultural adaptation, the IMPACT-III (HR) proves as a reliable and valid instrument to measure HRQOL in Croatian children with IBD.
Materials and methods

Participants and procedures
Children aged nine years or older with confirmed diagnosis of IBD for more than six months, according to the established criteria, 10 were included in this study. They were recruited at one of three pediatric gastroenterology units located in tertiary care hospitals in Croatia (two in city of Zagreb and one in Rijeka). Exclusion criterion was history of cognitive or developmental delay. One hundred and ten patients were consecutively enrolled between January 2009 and December 2011 within the either inpatient or outpatient clinic. Of them, 104 agreed to participate. Informed consent was obtained from a legal guardian prior to study procedures. Assessment was conducted on site and one researcher was always present. Children were instructed to firstly answer generic and then disease-specific HRQOL questionnaire. This study was approved by the governing Institutional Ethical Board at each recruitment site as well as by the Central Ethical Board at the School of Medicine University of Zagreb.
Measures
The recruiting physician collected demographic data and disease characteristics on all patients from medical records, including: age, sex, height and weight, disease type, disease location, disease duration, presence of surgical ostomies, number of relapses during the past six months, current and past drug and surgical treatment, family history for IBD. Current disease activity was assessed using Pediatric Crohn's Disease Activity Index (PCDAI) for Crohn's disease patients 11 and Pediatric Ulcerative Colitis Activity Index (PUCAI) for patients with ulcerative or indeterminate colitis. 12 To facilitate analysis of all IBD patients together, PCDAI and PUCAI scores were converted to categorical groupings ("inactive", "mild" and "moderate/severe") using established cut-scores. 13, 14 Disease severity groups were used to assess discriminant validity and test-retest reliability.
IMPACT-III Questionnaire
We used the IMPACT-III Questionnaire 2, 6 to examine aspects of quality of life in IBD-specific fields in our study sample. It is a self-report measure with 35 closed questions encompassing six proposed domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III uses 5-point Likert scale ranging from 1 to 5 for all answers. The outcome score ranges from 35 to 175, with higher scores suggesting better quality of life. 1 The questionnaire also includes a final open-ended question asking the participants to comment on anything else they feel is important.
As the IMPACT Questionnaire has not been previously used in Croatia, cross-cultural adaptation was required. This adaptation was to ensure that content validity of the questionnaire was maintained. Forward-and-backward translation, expert committee review, and cognitive debriefing were conducted according to Beaton et al. 15 with paraphrasing to determine whether each question and the response sets were understood and interpreted as intended. After receiving approval of translation process by the Developer, IMPACT-III (HR) was used.
PedsQL™
Participants also completed the Pediatric Quality of Life Inventory, Version 4.0 (PedsQL™) a generic 23-item measure of pediatric HRQOL. 16 This measure provides a total HRQOL score and two summary scores: physical health (comprised of the physical health domain score) and psychosocial health (comprised of the emotional, social and school functioning domain score). Participants rated the degree to which each item had been a problem for them during the past month on a 5-point Likert scale ranging from 0 (Never) to 4 (Almost Always). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores reflecting better HRQOL. 17 In the absence of a criterion standard to measure HRQOL in our sample of children with IBD, the PedsQL™ was used to evaluate concurrent validity. This indicates whether domains of IMPACT-III (HR) correlate with comparable domains of the PedsQL™.
There were 4 missing values for separate items in HRQOL questionnaires for two patients, which were dealt according to guidelines.
Statistical analysis
Descriptive statistics were used to describe the demographic and disease-related data for study participants. Independent samples t test were executed to evaluate whether demographic, anthropometric, disease-related variables, and mean HRQOL scores differed between recruitment sites.
Cronbach's alpha was calculated as a measure of internal consistency for reliability testing. Factor analysis was performed on data from IMPACT-III (HR) to help construct domains. Principal component analysis was conducted for 5-, 6-, 7-, 8-, and 9-factor (domain) structures using varimax rotation. Items were included in a domain when factor loadings (correlation between the item and the overall factor or domain) exceeded 0.3. 18 Based on these results items within the proposed domains were inspected to determine clinical relevance. Internal consistency was tested using Cronbach's alpha coefficients.
All analyses were conducted using parametric techniques, with testing to ensure that the assumption of a normal distribution was followed. Data distribution has been checked with Smirnov-Kolmogorov test. Where the assumption was not upheld, the nonparametric test was used. To compare mean IMPACT scores, analysis of variance (ANOVA) and independent samples t test were used, where appropriate. ANOVA was used to test the ability of IMPACT-III (HR) to distinguish differences in HRQOL scores in patients with different disease activity level scores (discriminant validity). To compare PedsQL™ and IMPACT-III (HR) (concurrent validity), the scores from IMPACT-III (HR) were transformed to a scale of 0 (worst possible HRQOL) to 100 (best possible HRQOL). The Pearson correlation coefficient assesses concurrence between domains of the two instruments. A strong correlation was defined as r N 0.5, a moderate correlation r ≥ 0.3, and a mild or weak correlation r b 0.3.
A P-value of b 0.05 was considered significant. The data were analyzed using Statistical Package for Social Sciences, Windows version 19.0.0.1 (SPSS Inc., Chicago, IL, USA) software.
Results
Participant characteristics
When comparing the three recruitment sites, no significant differences between variables of interest (demographics, disease characteristics and HRQOL scores) were observed (data not shown). As such, all analyses were conducted on the combined sample. All patients (104 of 104, 100%) completed IMPACT-III (HR) Questionnaire, while 6 patients (5.8%) did not complete PedsQL™. All participants were Caucasian with more females (N = 55, 52.9%) and patients with Crohn's disease (N = 74, 71.2%). There were 5 patients with indeterminate colitis and as such they were combined with ulcerative colitis group in final analysis. In addition to IBD, one patient had a diagnosis of primary sclerosing cholangitis, one had ankylosing spondylitis, and one was treated for intracranial tumor one year after the assessment. There were no significant differences in demographic or anthropometric variables between disease types. Demographics and disease characteristics of the 104 patients are shown in Table 1 . The most commonly affected site for Crohn's disease patients was ileocolonic region (52.7%). Eleven patients (14.9%) had involvement of the upper GI tract (mouth to ligament of Treitz) while perianal disease was present in three patients. Pancolitis was the most common disease location for colitis patients (53.3%), with inflammation extending beyond the splenic flexure.
Reliability testing
Cronbach's alpha score reflecting internal consistency was 0.92 for the IMPACT-III (HR) total score. The PedsQL™ also demonstrated adequate internal consistency analyzing the current sample with Cronbach's alpha 0.91. See Table 2 for mean values and Cronbach's alpha coefficients of total and original domain scores of IMPACT-III and PedsQL™.
Factor structure of IMPACT-III
Since one original domain (Tests & Treatments) had poor internal consistency (Table 2) , factor analysis was performed to explore domains for our study sample. The most statistically robust solution of principal component analysis was a 5-factor structure. The 5 domain titles (and Cronbach's alpha coefficients) chosen to describe these factors were (Table 3) : Symptoms (α 0.89), Concerns (α 0.86), Socializing (α 0.74), Body Image (α 0.64), and Worry about Stool (α 0.60). Questions 22 (How do you feel about tests you have to go through?) and 31 (How often did you have to pass wind in the last 2 weeks?) were loaded into specific domains, but their factor loadings were below 0.3. Furthermore, question 22 loaded equally across 3 domains (Concerns, Socializing, Body Image) suggesting that the question was ambiguous.
Concurrent validity
Comparing domains of IMPACT-III (HR) and the PedsQL™ showed significant correlations for all cases (Pb 0.001) which were strongest when similar domains were compared (Table 4) 
Discriminant validity
The total IMPACT-III (HR) score was significantly higher among patients with quiescent IBD (148.05 ± 13.94, N = 54) than among those with active disease (139.27 ± 18.81, N = 37 for mild, 124.63 ± 19.73, N = 8 for moderate/severe) (P b 0.001).
ANOVA showed significant differences in HRQOL scores between different symptom severity groups for the Symptoms scale (F = 10.98, P b 0.001), Socializing scale (F = 9.18, P b 0.001), and Worry about Stool scale (F = 10.44, P b 0.001) ( Table 5 ).
Qualitative feedback
Feedback from a section containing open-ended questions of the IMPACT-III (HR) highlighted the IBD symptoms or interventions that influenced patient's life and functioning. These included abdominal cramps after eating specific foods or after doing sports longer than usual, as well as concerns about doing another colonoscopy. Some suggested item rephrasing since questionnaire was more appropriate for patients taking oral treatment (this patient was not taking any drug therapy at the moment of assessment). One patient added that questionnaire focused too much on IBD being the main reason for all the problems ("all blue thoughts and tough time in life") on which she disagreed. The other commented inappropriateness of asking about girlfriend or boyfriend since they were too young to have one. Imposing the idea that they are special for having IBD and isolating them from society they considered unnecessary. Others prefer not to stand out because of their disease and to live normally, in spite of some impairment, especially in doing sports.
Discussion
Results of our study confirm that IMPACT-III (HR) is suitable for assessing HRQOL in children with IBD. The low percentage of questions left blank indicates that the questionnaire was not difficult to understand and complete. Factor analysis suggests that a 5-factor structure is more appropriate for IMPACT-III (HR) and the study population, although two questions were not included in this model. Removed questions did not load highly to a specific domain, or loaded on multiple domains and were removed in two separate validation studies as well (item 22 in study by Perrin et al. 8 and item 31 in study by Ogden et al. 9 ). The 5-factor structure was also suggested by Ogden et al. when validating IMPACT-III (UK), 9 whereas psychometric analysis of IMPACT-II from the United States by Perrin et al. 8 reported that a 4-factor structure was preferable. Six-domain structure remained for Canadian 2, 6 and Dutch 7 versions but their structure was based on clinical relevance and judgmental process rather than through a statistical approach such as factor analysis. Psychometric evaluation indicates that IMPACT-III (HR) has excellent internal structure and three factors demonstrated good internal reliability (0.74-0.89). Factor 4, Body Image, and factor 5, Worry about Stool, with 4 and 3 items respectively, had borderline acceptable reliability (0.64 and 0.60, respectively). Observed results suggest that items within each domain are related and measure the concept intended. In contrast to previous reports, 8 item loading reveals that children and adolescents distinguish between systemic and IBD symptoms. All 3 questions regarding the stool loaded separately from other items of original symptom domains (IBD Symptoms and , and e which is P = 0.008, P = 0.002, P = 0.009, P = 0.042, and P = 0.004 respectively. Systemic Symptoms). Adding questions about stool, may contribute to better internal reliability of the specific domain. The excellent level of internal consistency of the IMPACT-III (HR) (Cronbach's alpha = 0.92) satisfies recommended criteria (α N 0.90) for using it in individual patient decisions rather than only as the measurement for decisions for group of patients.
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Concurrent validity testing done in this study supports that IMPACT-III (HR) measures HRQOL in Croatian pediatric patients with IBD. Patients who perceived themselves as having poor HRQOL (using PedsQL™ scale) had lower IMPACT-III (HR) total scores. In addition, results of the discriminant validity testing support that the questionnaire is impacted by the patient's health status. Patients with quiescent disease had significantly greater mean total HRQOL scores, compared to patients having mild or moderate/severe disease activity (Table 5) . Hence, IMPACT-III (HR) can successfully discriminate between inactive and active disease. However, this is not a case between patients with mild and moderate/severe illness where significant difference in mean HRQOL scores was not observed despite significant difference of mean activity scores, P b 0.001 (19.5 vs. 42.5 for PCDAI and 19.6 vs. 33.8 for PUCAI). Similar result was reported in validity testing by Otley et al. 2 which was explained by lack of significant difference in the mean current disease activity. However, our ability to make this assessment is limited by low number of participants with moderate/severe activity (N = 8). Discriminant ability was not reported for Concerns and Body Image domains, since significant difference in mean scores was not observed between different severity groups (P = 0.93 and 0.54, respectively). However, scores followed observed trend for decreasing mean HRQOL score for increasing disease activity. This result is matching to the findings of IMPACT-III (UK) validation study 9 for Worries/Concerns About IBD and Body Image domains and it was contributed to the influence of other factors besides symptom severity on the extent to which children worry about their IBD or experience body image. It should not be expected that these 2 domains discriminate between patients who had no symptoms and those with mild or more severe symptoms, as measured by activity indices.
The current study has several strengths: use of wellvalidated measures to assess disease severity and HRQOL, multisite data collection (limits shared method bias), and recruitment from an inpatient sample also (avoiding prominent underrepresentation of patients with severe disease). To our knowledge, this is the first study reporting psychometric analysis of a disease-specific HRQOL questionnaire for children with IBD in this part of Europe. Considering the country's population (4 million) and an incidence of IBD comparable to those reported in Northern Europe, 20 a relatively large number of patients participated (50% of one-year's newly diagnosed). Lastly, this is the only study to yield quantitative data on HRQOL for pediatric IBD in Croatia.
We are aware of several limitations inherent to our study. First, test-retest reliability was not reported since period to reassessment was too long (6 to 12 months). Preliminary results show only moderate agreement (ICC = 0.45) for 27 repeated measures. The most common chosen interval for reliability testing is two weeks. Much longer interval further lowers the chance for participants to recall responses, but one could not be sure if other, unmeasured factors, could contribute to the perception of quality of life despite unchanged disease activity, localization, and child's treatment. For future studies that would employ IMPACT-III (HR), test-retest reliability analysis is strongly recommended. Secondly, randomization of participants was not performed and they were enrolled as they arrived to the recruitment site what could lead to selection bias. Finally, all of the original questions were developed through the item generation process and were retained through the item reduction process.
2 Therefore, they are all relevant to patients. In most cases, study population will skew the factor analysisas is likely the case with our sample. Less UC and IBD patients with severe disease activity in our study sample warrants caution when considering dropping any questionnaire items, despite results of factor analysis.
Conclusion
We have demonstrated that the IMPACT-III (HR) is valid and reliable measure of HRQOL in pediatric patients suffering from Crohn's disease or ulcerative colitis, and the 5-domain structure of IMPACT-III (HR) based on 33 items appears most appropriate for measuring HRQOL in Croatian children with IBD.
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